Epidemiology and determinants of non-diabetic hyperglycaemia and its conversion to type 2 diabetes mellitus, 2000-2015: cohort population study using UK electronic health records.
diabetes & endocrinology
epidemiology
primary care
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
06 09 2020
06 09 2020
Historique:
entrez:
7
9
2020
pubmed:
8
9
2020
medline:
15
5
2021
Statut:
epublish
Résumé
To study the characteristics of UK individuals identified with non-diabetic hyperglycaemia (NDH) and their conversion rates to type 2 diabetes mellitus (T2DM) from 2000 to 2015, using the Clinical Practice Research Datalink. Cohort study. UK primary Care Practices. Electronic health records identified 14 272 participants with NDH, from 2000 to 2015. Baseline characteristics and conversion trends from NDH to T2DM were explored. Cox proportional hazards models evaluated predictors of conversion. Crude conversion was 4% within 6 months of NDH diagnosis, 7% annually, 13% within 2 years, 17% within 3 years and 23% within 5 years. However, 1-year conversion fell from 8% in 2000 to 4% in 2014. Individuals aged 45-54 were at the highest risk of developing T2DM (HR 1.20, 95% CI 1.15 to 1.25- compared with those aged 18-44), and the risk reduced with older age. A body mass index (BMI) above 30 kg/m Although the rate of conversion from NDH to T2DM fell between 2010 and 2015, this is likely due to changes over time in the cut-off points for defining NDH, and more people of lower diabetes risk being diagnosed with NDH over time. People aged 45-54, smokers, depressed, with high BMI and more deprived are at increased risk of conversion to T2DM.
Identifiants
pubmed: 32893192
pii: bmjopen-2020-040201
doi: 10.1136/bmjopen-2020-040201
pmc: PMC7484863
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e040201Subventions
Organisme : Department of Health
ID : 16/48/07
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: National Institute for Health Research (Health Services and Delivery Research, 16/48/07 – Evaluating the NHS Diabetes Prevention Programme (NHS DPP): the DIPLOMA research programme (Diabetes Prevention – Long Term Multimethod Assessment)). Funded the time and facilities of RR. SH contributes for consultancy for Eli Lilly, NovoNordisk, Takeda, Sanofi Aventis, Zealand Pharma, UN-EEG and is also part of the speakers panel for NovoNordisk.
Références
PLoS One. 2014 Jun 18;9(6):e99825
pubmed: 24941260
PLoS One. 2016 Feb 26;11(2):e0146715
pubmed: 26918439
Diabet Med. 1996;13(3 Suppl 2):S9-11
pubmed: 8689862
BMJ Open. 2016 Feb 08;6(2):e010155
pubmed: 26857106
BMJ Open. 2016 Jan 13;6(1):e010210
pubmed: 26769791
Lancet. 1971 Feb 27;1(7696):405-12
pubmed: 4100731
BMC Med. 2019 Jul 25;17(1):145
pubmed: 31345214
Diabetes Metab Res Rev. 2010 Jul;26(5):378-85
pubmed: 20578203
BMC Fam Pract. 2010 Jan 05;11:1
pubmed: 20051110
Psychosom Med. 2001 Jul-Aug;63(4):619-30
pubmed: 11485116
Diabetes. 1997 Apr;46(4):701-10
pubmed: 9075814
Diabetologia. 2006 Jun;49(6):1175-8
pubmed: 16570158
Diabetologia. 2013 Jul;56(7):1489-93
pubmed: 23584433
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Diabetes Care. 2008 Feb;31(2):267-72
pubmed: 17989310
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
Pharmacoepidemiol Drug Saf. 2016 Dec;25(12):1375-1386
pubmed: 27193175
Diabetes. 2009 Apr;58(4):773-95
pubmed: 19336687
BMJ Open. 2017 Jan 25;7(1):e012905
pubmed: 28122831
Int J Epidemiol. 2011 Dec;40(6):1542-53
pubmed: 22158665
Lancet. 2012 Jun 16;379(9833):2279-90
pubmed: 22683128
Diabetes Res Clin Pract. 2016 Sep;119:71-4
pubmed: 27484296
BMJ. 2017 Jan 4;356:i6538
pubmed: 28052845
BMJ Open. 2014 Jun 09;4(6):e005002
pubmed: 24913327
N Engl J Med. 2011 Mar 24;364(12):1104-15
pubmed: 21428766